EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Prognostic significance of the C-reactive protein-to-lymphocyte ratio in patients with cancers

Xiaohui Liu, Shaobo Zhang, Yi Liu

Frontiers in Oncology · 21.08.2026 · 16

DOI: 10.3389/fonc.2026.1932997 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 21.08.2026. Verfasst von Xiaohui Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burns and Plastic Surgery & Wound Repair Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The C-reactive protein-to-lymphocyte ratio (CLR), a novel inflammation-based biomarker, has been reported to be associated with prognosis in various cancers. However, the prognostic significance of CLR remains controversial. Therefore, we performed a meta-analysis to comprehensively evaluate the prognostic value of CLR in patients with cancers.

Methods

Relevant studies were systematically searched in PubMed, Embase, and Web of Science up to March 21, 2026. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the association between CLR and survival outcomes, including overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS).

Results

A total of 22 studies from 18 articles involving 7220 patients were included. The pooled analysis demonstrated that elevated CLR was significantly associated with poorer OS (HR:1.65, 95% CI: 1.43-1.91), PFS (HR:1.53, 95% CI: 1.15-2.05), and DFS (HR:1.67, 95% CI: 1.41-1.97). Subgroup analysis further confirmed the prognostic value of CLR across country, treatment method, sample size, cancer type and analysis type.

Conclusions

Elevated CLR was significantly associated with unfavorable survival outcomes in cancers and may serve as a promising prognostic biomarker in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

C-reactive protein-to-lymphocyte ratiocancersmeta-analysisprognosissurvival outcome

Autor:innen und Institutionen

  • Department of Burns and Plastic Surgery & Wound Repair Surgery, the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Department of Thoracic Surgery, the Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.

Zitieren

APA

Liu, X., Zhang, S., & Liu, Y. (2026). Prognostic significance of the C-reactive protein-to-lymphocyte ratio in patients with cancers. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1932997

Vancouver

Liu X, Zhang S, Liu Y. Prognostic significance of the C-reactive protein-to-lymphocyte ratio in patients with cancers. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1932997

BibTeX
@article{Liu2026,
  author = {Liu, Xiaohui and Zhang, Shaobo and Liu, Yi},
  title = {Prognostic significance of the C-reactive protein-to-lymphocyte ratio in patients with cancers},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1932997}
}
Kostenlos starten →